For much of Foundayo’s development, one of the biggest questions around the drug was whether the liver would become a problem.

That concern was not contrived for clicks. Small-molecule (non-peptide) oral GLP-1 drugs had already produced enough liver-related trouble elsewhere in the field to make this industry observer… Cautious. Pfizer discontinued lotiglipron after transaminase elevations emerged in development, and danuglipron later raised its own liver concerns, and was abandoned. Foundayo, or orforglipron, was entering the market with that history sitting directly behind it.

A new pooled analysis from seven Phase 3 trials now gives a much clearer look at what actually happened in patients who received orforglipron, and the result is considerably more reassuring than the broader narrative around oral GLP-1 liver safety might suggest.

The analysis included nearly 7,000 patients treated with orforglipron. There were patients who developed substantial liver enzyme elevations, including one patient whose ALT rose to more than 10 times the upper limit of normal. That is the kind of number that looks alarming in isolation, particularly in a drug class already being watched closely for possible hepatotoxicity.

The broader pattern, however, did not look like a drug-induced liver injury signal. About 2.3% of patients receiving orforglipron developed ALT or AST elevations of at least three times the upper limit of normal without bilirubin elevations of at least two times the upper limit of normal. The rate among comparator patients was about 2.0%.

The more concerning combination of elevated transaminases and elevated bilirubin also failed to separate the drug from the control groups. Six patients receiving orforglipron met those laboratory thresholds, and six patients in the comparator group did as well.

Investigators reviewed those cases and identified alternative explanations, including biliary disease, acute viral hepatitis, Gilbert syndrome, and alcohol-associated cirrhosis. None of the orforglipron cases were ultimately classified as Hy’s Law drug-induced liver injury.

That is an important distinction because isolated liver enzyme elevations are not the same thing as proving a drug is damaging the liver. In a trial involving thousands of people with obesity and type 2 diabetes, some patients are going to develop marked abnormalities for reasons unrelated to the study drug. Gallbladder disease, viral illness, alcohol-associated disease, metabolic liver disease, and other medications can all move liver enzymes substantially.

The relevant question is whether those events occur more often in patients receiving the drug, whether they cluster in a consistent pattern, and whether the abnormalities behave in a way that points back to the medication. In this dataset, that pattern was not obvious.

The analysis also produced a finding that runs in the opposite direction of the original concern. Liver enzymes generally improved in patients receiving orforglipron, particularly among those who entered the studies with elevated values.

That is clinically relevant because obesity and type 2 diabetes are strongly associated with metabolic dysfunction-associated steatotic liver disease. Many patients entering obesity trials already have some degree of liver dysfunction before treatment begins. If weight loss and metabolic health improve, reductions in ALT and AST would not be surprising.

The result is an unusual contrast. The same program being closely watched for potential hepatotoxicity produced average liver enzyme changes that were more consistent with improving metabolic liver disease than worsening it.

The timing of the analysis is also notable because Foundayo has not exactly stormed out of the gate commercially. Novo Nordisk’s Wegovy pill has established a substantial early lead in the new oral obesity market, despite Foundayo having what would seem to be one obvious convenience advantage: it can be taken without the fasting and water restrictions attached to oral semaglutide.

The latest IQVIA prescription data cited by Citi put the Wegovy pill at roughly 181,000 weekly prescriptions, compared with about 44,000 for Foundayo. Foundayo is growing faster from its smaller base, up about 8% in the latest reported week compared with 3% for the Wegovy pill, but Novo is still filling roughly four oral obesity prescriptions for every one filled by Lilly.

The difference was even more pronounced when the launches were compared at the same point in time. By week 13, Foundayo was generating about 19,550 weekly prescriptions. The Wegovy pill had already surpassed 105,000 prescriptions by its own 13th week. Jefferies described Foundayo’s launch at the time as “muted.”

There is an important caveat to that comparison. Wegovy entered its launch with broad coverage already in place, while Foundayo had to wait until June for CVS, the last of the three major pharmacy benefit managers, to add coverage. That makes a clean head-to-head launch comparison difficult and gives Lilly a reasonable argument that Foundayo’s early prescription trajectory has been constrained by access as much as demand.

Still, awareness may be part of the problem too. The Wegovy pill also has another thing going for it. A shared name (and active ingredient) with one of the most popular obesity medicines on the market. With over 600,000 patients signed up for the Medicare bridge program, the industry is watching the numbers closely, as Lilly has made much of their efforts to educate doctors on the benefits of Foundayo.

That makes the liver analysis particularly useful for Lilly. Foundayo is still introducing an entirely new molecule to prescribers while competing against semaglutide, a drug physicians have been using for years and a Wegovy brand patients already know. Any lingering perception that a small-molecule oral GLP-1 may carry a unique liver liability could make that familiarity gap even harder to overcome.

A pooled Phase 3 dataset cannot solve a launch problem, but showing nearly 7,000 exposed patients without an apparent drug-induced liver injury signal removes one potential reason for clinicians to hesitate. For a product trying to convince physicians to choose a new molecule over one of the most familiar names in obesity medicine, that is not an insignificant development.

None of this eliminates the possibility of rare liver injury once Foundayo is used on a much larger scale. Idiosyncratic drug-induced liver injury can be difficult to detect before approval, particularly when the event is uncommon. Postmarketing surveillance remains appropriate, especially given the history of other oral small-molecule GLP-1 drugs.

What this analysis does change is the strength of the case that Foundayo itself is producing a meaningful liver toxicity signal. There were significant enzyme elevations, including patients with very high values, and there were cases that deserved careful adjudication. What did not emerge was a clear excess of those events in the orforglipron group, a Hy’s Law pattern, or a broad trend toward worsening liver function. Instead, average liver enzymes moved in the other direction.

For a drug that entered late-stage development under a cloud of liver scrutiny, and is now trying to make up ground against a much faster-starting Wegovy pill, that is an important result.

Foundayo’s liver story is not finished, and neither is its launch. But at this point, the safety concern looks less like an emerging liver problem and more like a theoretical risk that has so far failed to materialize in the large clinical dataset. The commercial question is whether prescribers and patients eventually see it the same way.